NEXTCURE, INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
NEXTCURE, INC (NXTC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.90% for the 6-month period ending 2026-06-30, per its S-4 filed 2026-08-18.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-18
- NEXTCURE, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.90%, a 11.36% decline year-over-year.
- NEXTCURE, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.40%.
- NEXTCURE, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 1.90%, a 31.41% decline from fiscal 2018.
- NEXTCURE, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2018 was 2.77%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.90% S-4 · filed 2026-08-18 | |||
| 2026-03-31 | 3.90% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 4.40% S-4 · filed 2026-08-18 | |||
| 2025-09-30 | 4.40% 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 4.40% S-4 · filed 2026-08-18 | |||
| 2025-03-31 | 4.40% 10-Q · filed 2026-05-07 | |||
| 2024-09-30 | 4.10% 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 4.10% 10-Q · filed 2025-08-07 | |||
| 2019-12-31 | 1.90% 10-K · filed 2021-03-04 | |||
| 2019-09-30 | 1.96% 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | 1.96% 10-Q · filed 2020-08-06 | |||
| 2018-12-31 | 2.77% 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |